IP Library Granted Patent US 10,307,465
Granted Patent B2
US 10,307,465 · App. 15/618,344 · Granted Jun 4, 2019

Pharmaceutical compositions and methods

Inventor: Steven Hoffman (Mahwah, NJ)
Assignee: Tyme, Inc.
A61K38/34A61K9/0019A61K9/0053A61K9/10A61K9/48A61K31/19A61K31/198A61K31/216A61K31/366A61K31/4166A61K31/436A61K31/55A61K31/787A61K38/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,307,465
App. No.
15/618,344
Granted
Jun 4, 2019
Kind
B2
Abstract

Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.

Claims (26)

1. A method of making cancer cells more accessible to oxidative stress, comprising contacting said cancer cells with an effective amount of a tyrosine hydroxylase inhibitor and assessing oxidative stress in said cancer cells.

2. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor accumulates in said cancer cells.

3. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor prevents formation of a coating of lipids in said cancer cells.

4. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor prevents formation of a coating of hyaluronan in said cancer cells.

5. The method of claim 1 , wherein said contacting is effected by administering said effective amount of said tyrosine hydroxylase inhibitor to a subject in whom said cancer cells reside.

6. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor is administered orally, subcutaneously, intravenously, transdermally, vaginally, or rectally.

7. The method of claim 1 , wherein said tyrosine hydroxylase inhibitor is a tyrosine derivative.

8. The method of claim 7 , wherein the tyrosine derivative is one or more of methyl (2R)-2-amino-3-(2-chloro-4 hydroxyphenyl) propanoate, D-tyrosine ethyl ester hydrochloride, methyl (2R)-2- amino-3-(2,6-dichloro-3,4-dimethoxyphenyl) propanoate H-D-Tyr(TBU)-allyl ester HCl, methyl (2R)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(4-[(2-chloro-6-fluorophenyl) methoxy] phenyl) propanoate, methyl (2R)-2- amino-3-(2-chloro-3,4-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl) propanoate, diethyl 2-(acetylamino)-2-(4-[(2-chloro-6-fluorobenzyl) oxy] benzyl malonate, methyl (2R)-2-amino-3-(3-chloro-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxy-5-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2,6- dichloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxyphenyl) propanoate, H-DL-tyr-OMe HCl, H-3,5-diiodo-tyr-Ome HCl, H-D-3,5-diiodo-tyr-OMe HCl, H-D-tyr-OMe HCl, D-tyrosine methyl ester hydrochloride, D-tyrosine-OMe HCl, methyl D-tyrosinate hydrochloride, (2R)-2-amino-3-(4-hydroxyphenyl) propionic acid, (2R)-2-amino-3-(4-hydroxyphenyl) methyl ester hydrochloride, methyl (2R)-2-amino-3-(4-hydroxyphenyl) propanoate hydrochloride, methyl (2R)-2-azanyl-3-(4-hydroxyphenyl) propanoate hydrochloride, 3-chloro-L-tyrosine, 3-nitro-L-tyrosine, 3-nitro-L-tyrosine ethyl ester hydrochloride, DL-m-tyrosine, DL-o-tyrosine, Boc-Tyr (3,5-I 2 )-OSu, Fmoc-tyr(3-NO 2 )-OH, and α-methyl-DL-tyrosine.

9. The method of claim 7 , wherein the tyrosine derivative is α-methyl-DL tyrosine.

10. A method of treating cancer in a subject comprising administering to the subject an amount of α-methyl-DL-tyrosine that is effective to make cancer cells in said subject more accessible to oxidative stress.

11. The method of claim 10 , wherein the cancer is non-small cell lung cancer, ovarian cancer, breast cancer, cervical cancer, pancreatic cancer, stomach cancer, brain cancer, liver cancer, testicular cancer, prostate cancer, leukemia, or lymphoma.

12. The method of claim 10 , wherein the cancer is metastatic cancer.

13. The method of claim 10 , wherein the cancer is breast cancer.

14. The method of claim 10 , wherein the cancer is prostate cancer.

15. The method of claim 10 , wherein the α-methyl-DL-tyrosine accumulates in the cancer cells and prevents the cancer cells from forming a coating of lipids.

16. The method of claim 10 , wherein the α-methyl-DL-tyrosine accumulates in the cancer cells and prevents the cancer cells from forming a coating of hyaluronan.

17. The method of claim 10 , wherein the cancer is non-small cell lung cancer.

18. The method of claim 10 , wherein the cancer is ovarian cancer.

19. The method of claim 10 , wherein the cancer is cervical cancer.

20. The method of claim 10 , wherein the cancer is pancreatic cancer.

21. The method of claim 10 , wherein the cancer is stomach cancer.

22. The method of claim 10 , wherein the cancer is brain cancer.

23. The method of claim 10 , wherein the cancer is liver cancer.

24. The method of claim 10 , wherein the cancer is testicular cancer.

25. The method of claim 10 , wherein the cancer is leukemia.

26. The method of claim 10 , wherein the cancer is lymphoma.

Assignments (2)
SECURITY INTEREST Recorded Dec 5, 2024
From: SYROS PHARMACEUTICALS, INC.; TYME TECHNOLOGIES, INC.; TYME INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069516/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2022
From: HOFFMAN, STEVEN
To: TYME, INC.
Reel/Frame 059892/0897 →
Continuity (7)
Continuation 15158679 · May 19, 2016
Continuation 14750877 · Jun 25, 2015
Continuation 13742865 · Jan 16, 2013
Continuation In Part 13371076 · Feb 10, 2012
Provisional Application 61587420 · Jan 17, 2012
Provisional Application 61702994 · Sep 12, 2012
Related Publication 20170274051A1 · Sep 28, 2017